AIM ImmunoTech Announces Release of the Next CEO Corner Segment
03 Julio 2024 - 7:55AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) today announced the
next CEO Corner segment has been published on the Company’s
website. For the CEO Corner segment, AIM Chief Executive Officer
Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study
of Ampligen and AstraZeneca’s Imfinzi as a combination therapy for
late-stage pancreatic cancer. The Company also provided a business
update, including that as a result of recent financings, AIM
recently had stockholders’ equity of $6.9 million.
The CEO Corner segment is now available
here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
AIM ImmunoTech (AMEX:AIM)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024